PT  - JOURNAL ARTICLE
AU  - Philip J.M. Brouwer
AU  - Tom G. Caniels
AU  - Karlijn van der Straten
AU  - Jonne L. Snitselaar
AU  - Yoann Aldon
AU  - Sandhya Bangaru
AU  - Jonathan L. Torres
AU  - Nisreen M.A. Okba
AU  - Mathieu Claireaux
AU  - Gius Kerster
AU  - Arthur E.H. Bentlage
AU  - Marlies M. van Haaren
AU  - Denise Guerra
AU  - Judith A. Burger
AU  - Edith E. Schermer
AU  - Kirsten D. Verheul
AU  - Niels van der Velde
AU  - Alex van der Kooi
AU  - Jelle van Schooten
AU  - Mariëlle J. van Breemen
AU  - Tom P. L. Bijl
AU  - Kwinten Sliepen
AU  - Aafke Aartse
AU  - Ronald Derking
AU  - Ilja Bontjer
AU  - Neeltje A. Kootstra
AU  - W. Joost Wiersinga
AU  - Gestur Vidarsson
AU  - Bart L. Haagmans
AU  - Andrew B. Ward
AU  - Godelieve J. de Bree
AU  - Rogier W. Sanders
AU  - Marit J. van Gils
TI  - Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
AID  - 10.1101/2020.05.12.088716
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.05.12.088716
4099  - http://biorxiv.org/content/early/2020/05/12/2020.05.12.088716.short
4100  - http://biorxiv.org/content/early/2020/05/12/2020.05.12.088716.full
AB  - The rapid spread of SARS-CoV-2 has a significant impact on global health, travel and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated neutralizing antibodies from convalescent COVID-19 patients using a SARS-CoV-2 stabilized prefusion spike protein. Several of these antibodies were able to potently inhibit live SARS-CoV-2 infection at concentrations as low as 0.007 µg/mL, making them the most potent human SARS-CoV-2 antibodies described to date. Mapping studies revealed that the SARS-CoV-2 spike protein contained multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as previously undefined non-RBD epitopes. In addition to providing guidance for vaccine design, these mAbs are promising candidates for treatment and prevention of COVID-19.Competing Interest StatementAmsterdam UMC has filed a patent application on COVID-19 monoclonal antibodies.